Bristol-Myers 2013 Earnings Forecast Beats Estimates

Prem Lachman, general partner and founder of Maximus Capital Management LLC, waits for the start of a Bristol-Myers Squibb Co. investor meeting in New York, U.S., on Thursday, March 4, 2010. Bristol-Myers Squibb Co. said earnings, excluding some costs, will drop to as low as $1.95 a share in 2013 from projected 2010 profit, as its top-selling drug, the blood thinner Plavix, loses patent protection. Photographer: Daniel Acker/Bloomberg via Getty Images
Prem Lachman, general partner and founder of Maximus Capital Management LLC, waits for the start of a Bristol-Myers Squibb Co. investor meeting in New York, U.S., on Thursday, March 4, 2010. Bristol-Myers Squibb Co. said earnings, excluding some costs, will drop to as low as $1.95 a share in 2013 from projected 2010 profit, as its top-selling drug, the blood thinner Plavix, loses patent protection. Photographer: Daniel Acker/Bloomberg via Getty Images
Bristol-Myers 2013 Earnings Forecast Beats Estimates
LICENTIE KOPEN
Hoe mag ik dit beeld gebruiken?
€ 335,00
EUR
Getty ImagesBristol-Myers 2013 Earnings Forecast Beats Estimates, Nieuwsfoto'sBristol-Myers 2013 Earnings Forecast Beats Estimates, Nieuwsfoto'sBristol-Myers 2013 Earnings Forecast Beats Estimates Vind hoogwaardige nieuwsfoto's in een hoge resolutie op Getty ImagesProduct #:97438589
€475€150
Getty Images
In stock

GEGEVENS

Beperkingen:
Neem voor gebruik voor alle commerciële of promotiedoeleinden contact op met uw lokale kantoor.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credits:
Bloomberg / Contributor
Redactioneel nr.:
97438589
Collectie:
Bloomberg
Gemaakt op:
04 maart 2010
Datum van uploaden:
Soort licentie:
Rights managed
Release-informatie:
Geen release. Meer informatie
Bron:
Bloomberg
Naam materiaal:
BRISTOL MYERS BEATS FORECAST